Cardiovascular Pharmacogenetics

Peters, Bas J M; Boer, Anthonius de; Schalekamp, Tom; Klungel, Olaf H.; Zee, Anke‐Hilse Maitland‐van der

doi:10.1002/9781118116494.ch6

Cited by 2 publications

(2 citation statements)

References 201 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…6 In addition to the variation that can be attributed to various sociodemographic characteristics, genetic determinants of drug response have been identified, which can affect the way drugs are metabolized, absorbed, and distributed. 1,[6][7][8] Therefore, genetic information can be used to inform risk factor identification, drug dose responses, side effects management, and outcome prediction. [9][10][11] PGx-guided drug prescribing holds enormous potential for individualizing CVD management and reducing the risks of drug-related adverse events.…”

Section: Introductionmentioning

confidence: 99%

Systematic review of the evidence on the cost-effectiveness of pharmacogenomics-guided treatment for cardiovascular diseases

Zhu

Swanson

Rojas

et al. 2020

Genetics in Medicine

View full text Add to dashboard Cite

Purpose: To examine the evidence on the cost-effectiveness of implementing pharmacogenomics (PGx) in cardiovascular disease (CVD) care. Methods: We conducted a systematic review using multiple databases from inception to 2018. The titles and abstracts of costeffectiveness studies on PGx-guided treatment in CVD care were screened, and full texts were extracted. Results: We screened 909 studies and included 46 to synthesize. Acute coronary syndrome and atrial fibrillation were the predominantly studied conditions (59%). Most studies (78%) examined warfarin-CYP2C9/VKORC1 or clopidogrel-CYP2C19. A payer's perspective was commonly used (39%) for cost calculations, and most studies (46%) were US-based. The majority (67%) of the studies found PGx testing to be cost-effective in CVD care, but costeffectiveness varied across drugs and conditions. Two studies examined PGx panel testing, of which one examined pre-emptive testing strategies. Conclusion: We found mixed evidence on the cost-effectiveness of PGx in CVD care. Supportive evidence exists for clopidogrel-CYP2C19 and warfarin-CYP2C9/VKORC1, but evidence is limited in other drug-gene combinations. Gaps persist, including unclear explanation of perspective and cost inputs, underreporting of study design elements critical to economic evaluations, and limited examination of PGx panel and pre-emptive testing for their costeffectiveness. This review identifies the need for further research on economic evaluations of PGx implementation.

show abstract

Section: Introductionmentioning

confidence: 99%

Systematic review of the evidence on the cost-effectiveness of pharmacogenomics-guided treatment for cardiovascular diseases

Zhu

Swanson

Rojas

et al. 2020

Genetics in Medicine

View full text Add to dashboard Cite

show abstract

“…In addition, polymorphisms in AGTR1 have been associated with muscle toxicity in patients treated with statins (13). In addition to AGTR1, angiotensinogen (AGT) is part of the renin-angiotensin-aldosterone system (14). An improved response to diuretics has been observed in the presence of the AGTR1 A1166C and AGT G-6A polymorphisms in African-American women and a Chinese population (15,16).…”

Section: Introductionmentioning

confidence: 99%

Effect of AGTR1 and BDKRB2 gene polymorphisms on atorvastatin metabolism in a Mexican population

et al. 2017

View full text Add to dashboard Cite

Abstract. Discrepancies in the response to drugs are partially due to polymorphisms in genes involved in drug metabolism and transport. The frequency, pattern and impact of these polymorphisms vary among populations. In the present study, the pharmacokinetics and pharmacogenetics of atorvastatin (ATV) in a Mexican population were investigated. The study cohort exhibited differing ATV metabolizing phenotypes, and in subsequent allelic discrimination assays, single nucleotide polymorphisms in the angiotensinogen, angiotensin II type 1 receptor (AGTR1) and bradykinin B2 receptor (BDKRB2) genes were genotyped and their effects on the pharmacokinetic parameters of ATV were assessed. Additionally, association studies were performed to test for a correlation between metabolizing phenotypes and genetic variants. It was observed that carriers of the genotypes A/C and C/T in AGTR1 and BDKRB2 had higher area under the plasma concentration-time curve values from time 0 to the time of the last measurement and from time 0 extrapolated to infinity, and lower values of clearance of the fraction dose absorbed compared with homozygous carriers (P<0.05). Only the C/C genotype of BDKRB2 was associated with the fast metabolizer phenotype. These data suggest that AGTR1 and BDKRB2 are involved in ATV pharmacokinetics; a novel finding that requires confirmation in further studies.

show abstract

Cardiovascular Pharmacogenetics

Cited by 2 publications

References 201 publications

Systematic review of the evidence on the cost-effectiveness of pharmacogenomics-guided treatment for cardiovascular diseases

Systematic review of the evidence on the cost-effectiveness of pharmacogenomics-guided treatment for cardiovascular diseases

Effect of AGTR1 and BDKRB2 gene polymorphisms on atorvastatin metabolism in a Mexican population

Contact Info

Product

Resources

About